The science of cerebral ischemia and the quest for neuroprotection: Navigating past failure to future success - A review

Journal of Neurosurgery

Volumn 118, Issue 5, 2013, Pages 1072-1085

  Turner, Ryan C ^a   Dodson, Sean C ^a   Rosen, Charles L ^a   Huber, Jason D ^a,b  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Age; Ischemic stroke; Neuroprotection; Pathophysiology; Vascular disorders

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; AMPA RECEPTOR; APTIGANEL; ARUNDIC ACID; CHEMOKINE; CLOMETHIAZOLE; CYTOCHROME C; CYTOKINE; DEXTROMETHORPHAN; DISUFENTON SODIUM; FLINDOKALNER; FLUOROCITRIC ACID; GAVESTINEL; GLUTAMIC ACID; HIGH MOBILITY GROUP B1 PROTEIN; ION CHANNEL; KAPPA OPIATE RECEPTOR; LUBELUZOLE; MATRIX METALLOPROTEINASE; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALMEFENE; NEUROPROTECTIVE AGENT; NIMODIPINE; REPINOTAN; ROVELIZUMAB; TACROLIMUS; TANTALUM; TIRILAZAD; UNINDEXED DRUG; ZONAMPANEL;

APOPTOSIS; ASTROCYTE; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; DEPOLARIZATION; EXCITOTOXICITY; GENDER; GLIA; HUMAN; LIPID PEROXIDATION; MICROGLIA; NERVE CELL; NEUROMODULATION; NEUROPROTECTION; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; RISK ASSESSMENT;

BRAIN ISCHEMIA; HMGB1 PROTEIN; HUMANS; MATRIX METALLOPROTEINASES; NEUROGLIA; NEUROPROTECTIVE AGENTS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84877761687     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2012.11.JNS12408     Document Type: Review

References (116)

1. Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM: Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke 26:254-258, 1995
2. Albers GW, Goldstein LB, Hall D, Lesko LM: Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. JAMA 286:2673-2682, 2001 (Pubitemid 33135073)
3. Astrup J, Symon L, Branston NM, Lassen NA: Cortical evoked potential and extracellular K+ and H+ at critical levels of brain ischemia. Stroke 8:51-57, 1977
4. Badan I, Buchhold B, Hamm A, Gratz M, Walker LC, Platt D, et al: Accelerated glial reactivity to stroke in aged rats correlates with reduced functional recovery. J Cereb Blood Flow Metab 23:845-854, 2003 (Pubitemid 36818692)
5. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM: Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 56:1015-1020, 2001 (Pubitemid 32336306)
6. Becker KJ: Anti-leukocyte antibodies: LeukArrest (Hu23F2G) and Enlimomab (R6.5) in acute stroke. Curr Med Res Opin 18 (Suppl 2):s18-s22, 2002
7. Block ML, Zecca L, Hong JS: Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8:57-69, 2007 (Pubitemid 46011999)
8. Bordi F, Pietra C, Ziviani L, Reggiani A: The glycine antagonist GV150526 protects somatosensory evoked potentials and reduces the infarct area in the MCAo model of focal ischemia in the rat. Exp Neurol 145:425-433, 1997 (Pubitemid 27314793)
9. Bowes MP, Rothlein R, Fagan SC, Zivin JA: Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology 45:815-819, 1995
10. Braeuninger S, Kleinschnitz C: Rodent models of focal cerebral ischemia: procedural pitfalls and translational problems. Exp Transl Stroke Med 1:8, 2009
11. Bredesen DE: Apoptosis: overview and signal transduction pathways. J Neurotrauma 17:801-810, 2000
12. Broughton BR, Reutens DC, Sobey CG: Apoptotic mechanisms after cerebral ischemia. Stroke 40:e331-e339, 2009
13. Burns TC, Steinberg GK: Stem cells and stroke: opportunities, challenges and strategies. Expert Opin Biol Ther 11:447-461, 2011
14. Candelario-Jalil E: Injury and repair mechanisms in ischemic stroke: considerations for the development of novel neurotherapeutics. Curr Opin Investig Drugs 10:644-654, 2009
15. Carmignoto G, Gómez-Gonzalo M: The contribution of astrocyte signalling to neurovascular coupling. Brain Res Brain Res Rev 63:138-148, 2010
16. Cheney JA, Weisser JD, Bareyre FM, Laurer HL, Saatman KE, Raghupathi R, et al: The maxi-K channel opener BMS-204352 attenuates regional cerebral edema and neurologic motor impairment after experimental brain injury. J Cereb Blood Flow Metab 21:396-403, 2001 (Pubitemid 32298886)
17. Clark WM, Raps EC, Tong DC, Kelly RE: Cervene (Nalmefene) in acute ischemic stroke: final results of a phase III efficacy study. Stroke 31:1234-1239, 2000 (Pubitemid 30351239)
18. Cotrina ML, Nedergaard M: Astrocytes in the aging brain. J Neurosci Res 67:1-10, 2002
19. Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, et al: Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 31:347-354, 2000 (Pubitemid 30078164)
20. De Ryck M, Keersmaekers R, Duytschaever H, Claes C, Clincke G, Janssen M, et al: Lubeluzole protects sensorimotor function and reduces infarct size in a photochemical stroke model in rats. J Pharmacol Exp Ther 279:748-758, 1996 (Pubitemid 27166848)
21. del Zoppo GJ: The neurovascular unit in the setting of stroke. J Intern Med 267:156-171, 2010
22. Diener HC, Cortens M, Ford G, Grotta J, Hacke W, Kaste M, et al: Lubeluzole in acute ischemic stroke treatment: a double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke 31:2543-2551, 2000
23. Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al: NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke 39:1751-1758, 2008
24. Dinapoli VA, Benkovic SA, Li X, Kelly KA, Miller DB, Rosen CL, et al: Age exaggerates proinflammatory cytokine signaling and truncates signal transducers and activators of transcription 3 signaling following ischemic stroke in the rat. Neuroscience 170:633-644, 2010
25. Du C, Hu R, Hsu CY, Choi DW: Dextrorphan reduces infarct volume, vascular injury, and brain edema after ischemic brain injury. J Neurotrauma 13:215-222, 1996 (Pubitemid 26142614)
26. Durukan A, Strbian D, Tatlisumak T: Rodent models of ischemic stroke: a useful tool for stroke drug development. Curr Pharm Des 14:359-370, 2008 (Pubitemid 351516859)
27. Enlimomab Acute Stroke Trial Investigators: Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology 57:1428-1434, 2001
28. Faden AI, Shirane R, Chang LH, James TL, Lemke M, Weinstein PR: Opiate-receptor antagonist improves metabolic recovery and limits neurochemical alterations associated with reperfusion after global brain ischemia in rats. J Pharmacol Exp Ther 255:451-458, 1990
29. Fagan SC, Cronic LE, Hess DC: Minocycline development for acute ischemic stroke. Transl Stroke Res 2:202-208, 2011
30. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, et al: Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 40:2244-2250, 2009
31. Fogelholm R, Erilä T, Palomäki H, Murros K, Kaste M: Effect of nimodipine on final infarct volume after acute ischemic stroke. Cerebrovasc Dis 10:189-193, 2000 (Pubitemid 30219245)
32. Graham SH, Chen J, Simon RP: A dose-response study of dextrorphan in permanent focal ischemia. Neurosci Lett 160:21-23, 1993 (Pubitemid 23287592)
33. Guevara R, Gianotti M, Oliver J, Roca P: Age and sex-related changes in rat brain mitochondrial oxidative status. Exp Gerontol 46:923-928, 2011
34. Hayakawa K, Mishima K, Nozako M, Hazekawa M, Mishima S, Fujioka M, et al: Delayed treatment with minocycline ameliorates neurologic impairment through activated microglia expressing a high-mobility group box1-inhibiting mechanism. Stroke 39:951-958, 2008 (Pubitemid 351619558)
35. Hayakawa K, Nakano T, Irie K, Higuchi S, Fujioka M, Orito K, et al: Inhibition of reactive astrocytes with fluorocitrate retards neurovascular remodeling and recovery after focal cerebral ischemia in mice. J Cereb Blood Flow Metab 30:871-882, 2010
36. Hayakawa K, Qiu J, Lo EH: Biphasic actions of HMGB1 signaling in inflammation and recovery after stroke. Ann N Y Acad Sci 1207:50-57, 2010
37. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al: Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123:933-944, 2011
38. Hellström HO, Wanhainen A, Valtysson J, Persson L, Hillered L: Effect of tirilazad mesylate given after permanent middle cerebral artery occlusion in rat. Acta Neurochir (Wien) 129:188-192, 1994 (Pubitemid 24274565)
39. Horn J, de Haan RJ, Vermeulen M, Limburg M: Very Early Nimodipine Use in Stroke (VENUS): a randomized, double-blind, placebo-controlled trial. Stroke 32:461-465, 2001 (Pubitemid 32155235)
40. Hossmann KA: Pathophysiological basis of translational stroke research. Folia Neuropathol 47:213-227, 2009
41. Hossmann KA: Pathophysiology and therapy of experimental stroke. Cell Mol Neurobiol 26:1057-1083, 2006
42. Huang J, Upadhyay UM, Tamargo RJ: Inflammation in stroke and focal cerebral ischemia. Surg Neurol 66:232-245, 2006 (Pubitemid 44279808)
43. Jensen BS: BMS-204352: a potassium channel opener developed for the treatment of stroke. CNS Drug Rev 8:353-360, 2002
44. Jin R, Yang G, Li G: Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol 87:779-789, 2010
45. Jin R, Yang G, Li G: Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis 38:376-385, 2010
46. Johnson EM Jr, Greenlund LJ, Akins PT, Hsu CY: Neuronal apoptosis: current understanding of molecular mechanisms and potential role in ischemic brain injury. J Neurotrauma 12:843-852, 1995
47. Joly LM, Mucignat V, Mariani J, Plotkine M, Charriaut-Marlangue C: Caspase inhibition after neonatal ischemia in the rat brain. J Cereb Blood Flow Metab 24:124-131, 2004 (Pubitemid 38021276)
48. Jordán J, Segura T, Brea D, Galindo MF, Castillo J: Inflammation as therapeutic objective in stroke. Curr Pharm Des 14:3549-3564, 2008
49. Kelly KA, Li X, Tan Z, VanGilder RL, Rosen CL, Huber JD: NOX2 inhibition with apocynin worsens stroke outcome in aged rats. Brain Res 1292:165-172, 2009
50. Kristián T, Siesjö BK: Calcium in ischemic cell death. Stroke 29:705-718, 1998
51. Kunz A, Dirnagl U, Mergenthaler P: Acute pathophysiological processes after ischaemic and traumatic brain injury. Best Pract Res Clin Anaesthesiol 24:495-509, 2010
52. Labiche LA, Grotta JC: Clinical trials for cytoprotection in stroke. NeuroRx 1:46-70, 2004 (Pubitemid 46591882)
53. Lacy CR, Suh DC, Bueno M, Kostis JB: Delay in presentation and evaluation for acute stroke: Stroke Time Registry for Outcomes Knowledge and Epidemiology (S.T.R.O.K.E.). Stroke 32:63-69, 2001 (Pubitemid 32063825)
54. Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, et al: Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 69:1404-1410, 2007 (Pubitemid 47511461)
55. Lees KR, Asplund K, Carolei A, Davis SM, Diener HC, Kaste M, et al: Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. Lancet 355:1949-1954, 2000 (Pubitemid 30326099)
56. Liu F, Yuan R, Benashski SE, McCullough LD: Changes in experimental stroke outcome across the life span. J Cereb Blood Flow Metab 29:792-802, 2009
57. Liu S, Zhen G, Meloni BP, Campbell K, Winn HR: Rodent stroke model guidelines for preclinical stroke trials (1st edition). J Exp Stroke Transl Med 2:2-27, 2009
58. Lo EH: Experimental models, neurovascular mechanisms and translational issues in stroke research. Br J Pharmacol 153 (Suppl 1):S396-S405, 2008
59. Lo EH: A new penumbra: transitioning from injury into repair after stroke. Nat Med 14:497-500, 2008
60. Lo EH, Dalkara T, Moskowitz MA: Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 4:399-415, 2003 (Pubitemid 37280178)
61. Lyden P, Shuaib A, Ng K, Levin K, Atkinson RP, Rajput A, et al: Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results. Stroke 33:122-128, 2002 (Pubitemid 34052197)
62. Macleod MR, O'Collins T, Horky LL, Howells DW, Donnan GA: Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow Metab 25:713-721, 2005 (Pubitemid 40705606)
63. MacManus JP, Buchan AM: Apoptosis after experimental stroke: fact or fashion? J Neurotrauma 17:899-914, 2000
64. Madden KP, Clark WM, Zivin JA: Delayed therapy of experimental ischemia with competitive N-methyl-D-aspartate antagonists in rabbits. Stroke 24:1068-1071, 1993 (Pubitemid 23201468)
65. Maeda M, Furuichi Y, Noto T, Matsuoka N, Mutoh S, Yoneda Y: Tacrolimus (FK506) suppresses rt-PA-induced hemorrhagic transformation in a rat thrombotic ischemia stroke model. Brain Res 1254:99-108, 2009
66. Marshall JW, Cross AJ, Ridley RM: Functional benefit from clomethiazole treatment after focal cerebral ischemia in a nonhuman primate species. Exp Neurol 156:121-129, 1999 (Pubitemid 29152989)
67. Mauler F, Horváth E: Neuroprotective efficacy of repinotan HCl, a 5-HT1A receptor agonist, in animal models of stroke and traumatic brain injury. J Cereb Blood Flow Metab 25:451-459, 2005
68. McCullough LD, Alkayed NJ, Traystman RJ, Williams MJ, Hurn PD: Postischemic estrogen reduces hypoperfusion and secondary ischemia after experimental stroke. Stroke 32:796-802, 2001
69. Meadows ME, Fisher M, Minematsu K: Delayed treatment with a noncompetitive nmda antagonist, CNS-1102, reduces infarct size in rats. Cerebrovasc Dis 4:26-31, 1994 (Pubitemid 2029653)
70. Meden P, Overgaard K, Pedersen H, Boysen G: Effect of early treatment with tirilazad (u74006f) combined with delayed thrombolytic therapy in rat embolic stroke. Cerebrovasc Dis 6:141-148, 1996 (Pubitemid 26148409)
71. Mizoguchi H, Leitermann RJ, Narita M, Nagase H, Suzuki T, Tseng LF: Region-dependent G-protein activation by kappa-opioid receptor agonists in the mouse brain. Neurosci Lett 356:145-147, 2004 (Pubitemid 38121489)
72. Muir KW: Magnesium in stroke treatment. Postgrad Med J 78:641-645, 2002
73. Nakamura H, Strong AJ, Dohmen C, Sakowitz OW, Vollmar S, Sué M, et al: Spreading depolarizations cycle around and enlarge focal ischaemic brain lesions. Brain 133:1994-2006, 2010
74. Nakanishi H, Wu Z: Microglia-aging: roles of microglial lysosome- and mitochondria-derived reactive oxygen species in brain aging. Behav Brain Res 201:1-7, 2009
75. Nakase T, Maeda T, Yoshida Y, Nagata K: Ischemia alters the expression of connexins in the aged human brain. J Biomed Biotechnol 2009:147946, 2009
76. North American Glycine Antagonist in Neuroprotection (GAIN) Investigators: Phase II studies of the glycine antagonist GV150526 in acute stroke: the North American experience. Stroke 31:358-365, 2000
77. Nuttall ME, Lee D, McLaughlin B, Erhardt JA: Selective inhibitors of apoptotic caspases: implications for novel therapeutic strategies. Drug Discov Today 6:85-91, 2001 (Pubitemid 32101510)
78. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW: 1,026 experimental treatments in acute stroke. Ann Neurol 59:467-477, 2006 (Pubitemid 43358067)
79. Orset C, Haelewyn B, Vivien K, Vivien D, Young AR: Rodent models of thromboembolic stroke, in Dirnagl U (ed): Rodent Models of Stroke. New York: Springer, 2010, Vol 47, pp 55-70
80. Pettigrew LC, Kasner SE, Albers GW, Gorman M, Grotta JC, Sherman DG, et al: Safety and tolerability of arundic acid in acute ischemic stroke. J Neurol Sci 251:50-56, 2006 (Pubitemid 44792138)
81. Pilegaard K, Ladefoged O: Total number of astrocytes in the molecular layer of the dentate gyrus of rats at different ages. Anal Quant Cytol Histol 18:279-285, 1996 (Pubitemid 26277443)
82. Popa-Wagner A, Carmichael ST, Kokaia Z, Kessler C, Walker LC: The response of the aged brain to stroke: too much, too soon? Curr Neurovasc Res 4:216-227, 2007 (Pubitemid 47235973)
83. Robertson GS, Crocker SJ, Nicholson DW, Schulz JB: Neuroprotection by the inhibition of apoptosis. Brain Pathol 10:283-292, 2000 (Pubitemid 30181097)
84. Roda JM, Carceller F, Díez-Tejedor E, Avendaño C: Reduction of infarct size by intra-arterial nimodipine administered at reperfusion in a rat model of partially reversible brain focal ischemia. Stroke 26:1888-1892, 1995
85. Rosen CL, Dinapoli VA, Nagamine T, Crocco T: Influence of age on stroke outcome following transient focal ischemia. J Neurosurg 103:687-694, 2005 (Pubitemid 43193876)
86. Rossi DJ, Brady JD, Mohr C: Astrocyte metabolism and signaling during brain ischemia. Nat Neurosci 10:1377-1386, 2007 (Pubitemid 350014689)
87. Saver JL, Kidwell C, Eckstein M, Starkman S: Prehospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial. Stroke 35:e106-e108, 2004
88. Savitz SI: A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol 205:20-25, 2007
89. Semkova I, Wolz P, Krieglstein J: Neuroprotective effect of 5-HT1A receptor agonist, Bay X 3702, demonstrated in vitro and in vivo. Eur J Pharmacol 359:251-260, 1998 (Pubitemid 28513022)
90. Shuaib A, Hussain MS: The past and future of neuroprotection in cerebral ischaemic stroke. Eur Neurol 59:4-14, 2008 (Pubitemid 350277253)
91. Shuaib A, Ijaz S, Kanthan R: Clomethiazole protects the brain in transient forebrain ischemia when used up to 4 h after the insult. Neurosci Lett 197:109-112, 1995
92. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al: NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 357:562-571, 2007 (Pubitemid 47236281)
93. Siesjö BK: Pathophysiology and treatment of focal cerebral ischemia. Part I: Pathophysiology. J Neurosurg 77:169-184, 1992
94. Smith WS: Pathophysiology of focal cerebral ischemia: a therapeutic perspective. J Vasc Interv Radiol 15:S3-S12, 2004
95. Sorbera LA, Castaner J, Castaner RM: Arundic acid. Drugs Future 29:441-449, 2004
96. Stankowski JN, Gupta R: Therapeutic targets for neuroprotection in acute ischemic stroke: lost in translation? Antioxid Redox Signal 14:1841-1851, 2011
97. Starkov AA, Chinopoulos C, Fiskum G: Mitochondrial calcium and oxidative stress as mediators of ischemic brain injury. Cell Calcium 36:257-264, 2004 (Pubitemid 38992351)
98. Stroke Therapy Academic Industry Roundtable (STAIR): Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30:2752-2758, 1999
99. Suzuki M, Sasamata M, Miyata K: Neuroprotective effects of YM872 coadministered with t-PA in a rat embolic stroke model. Brain Res 959:169-172, 2003 (Pubitemid 35435418)
100. Switzer JA, Hess DC, Ergul A, Waller JL, Machado LS, Portik-Dobos V, et al: Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. Stroke 42:2633-2635, 2011
101. Takamatsu H, Tsukada H, Noda A, Kakiuchi T, Nishiyama S, Nishimura S, et al: FK506 attenuates early ischemic neuronal death in a monkey model of stroke. J Nucl Med 42:1833-1840, 2001 (Pubitemid 34016354)
102. Takano T, Oberheim N, Cotrina ML, Nedergaard M: Astrocytes and ischemic injury. Stroke 40 (3 Suppl):S8-S12, 2009
103. Tateishi N, Mori T, Kagamiishi Y, Satoh S, Katsube N, Morikawa E, et al: Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: suppression of astrocytic activation by a novel agent (R)-(-) -2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits. J Cereb Blood Flow Metab 22:723-734, 2002 (Pubitemid 34596465)
104. Teal P, Davis S, Hacke W, Kaste M, Lyden PD, Fierus M: A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT). Stroke 40:3518-3525, 2009
105. Tirilazad International Steering Committee: Tirilazad mesylate in acute ischemic stroke: a systematic review. Stroke 31:2257-2265, 2000 (Erratum in Stroke 32:279, 2001)
106. Toung TJ, Traystman RJ, Hurn PD: Estrogen-mediated neuroprotection after experimental stroke in male rats. Stroke 29:1666-1670, 1998 (Pubitemid 28365591)
107. Tripathy D, Yin X, Sanchez A, Luo J, Martinez J, Grammas P: Cerebrovascular expression of proteins related to inflammation, oxidative stress and neurotoxicity is altered with aging. J Neuroinflammation 7:63, 2010
108. Vibulsresth S, Dietrich WD, Busto R, Ginsberg MD: Failure of nimodipine to prevent ischemic neuronal damage in rats. Stroke 18:210-216, 1987 (Pubitemid 17016710)
109. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI: A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345:1243-1249, 2001 (Pubitemid 34951488)
110. Wang Q, Tang XN, Yenari MA: The inflammatory response in stroke. J Neuroimmunol 184:53-68, 2007 (Pubitemid 46365991)
111. Wang X, Han W, Du X, Zhu C, Carlsson Y, Mallard C, et al: Neuroprotective effect of Bax-inhibiting peptide on neonatal brain injury. Stroke 41:2050-2055, 2010
112. Weiser T: AMPA receptor antagonists for the treatment of stroke. Curr Drug Targets CNS Neurol Disord 4:153-159, 2005
113. Yang Y, Li Q, Ahmad F, Shuaib A: Survival and histological evaluation of therapeutic window of post-ischemia treatment with magnesium sulfate in embolic stroke model of rat. Neurosci Lett 285:119-122, 2000 (Pubitemid 30227634)
114. Yenari MA, Kunis D, Sun GH, Onley D, Watson L, Turner S, et al: Hu23F2G, an antibody recognizing the leukocyte CD11/CD18 integrin, reduces injury in a rabbit model of transient focal cerebral ischemia. Exp Neurol 153:223-233, 1998 (Pubitemid 28489889)
115. Zipfel GJ, Babcock DJ, Lee JM, Choi DW: Neuronal apoptosis after CNS injury: the roles of glutamate and calcium. J Neurotrauma 17:857-869, 2000
116. Zonta M, Angulo MC, Gobbo S, Rosengarten B, Hossmann KA, Pozzan T, et al: Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. Nat Neurosci 6:43-50, 2003 (Pubitemid 36026331)